TOCCI, VERA
 Distribuzione geografica
Continente #
EU - Europa 242
NA - Nord America 154
AS - Asia 103
SA - Sud America 13
OC - Oceania 1
Totale 513
Nazione #
US - Stati Uniti d'America 146
IT - Italia 143
SG - Singapore 91
DE - Germania 50
FI - Finlandia 19
BR - Brasile 11
GB - Regno Unito 9
CN - Cina 7
AT - Austria 5
CA - Canada 5
NL - Olanda 4
EE - Estonia 3
MX - Messico 3
PL - Polonia 2
SE - Svezia 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AU - Australia 1
BD - Bangladesh 1
BG - Bulgaria 1
ES - Italia 1
FR - Francia 1
IN - India 1
IQ - Iraq 1
LT - Lituania 1
SK - Slovacchia (Repubblica Slovacca) 1
TR - Turchia 1
UY - Uruguay 1
Totale 513
Città #
Singapore 55
Munich 40
Santa Clara 21
Ashburn 19
Chandler 17
Palermo 14
Rome 13
Turku 11
Milan 9
Helsinki 8
Catanzaro 6
Chicago 6
Naples 6
Livorno 5
London 5
Reggio Calabria 5
Bari 4
Edmonton 4
Lawrence 4
Los Angeles 4
Princeton 4
Washington 4
Council Bluffs 3
Benevento 2
Boston 2
Catania 2
Cortale 2
Honolulu 2
Lavello 2
Messina 2
New York 2
Piazza Armerina 2
Scorrano 2
Swindon 2
São Paulo 2
Vallefiorita 2
Wilmington 2
Abu Dhabi 1
Ann Arbor 1
Belo Horizonte 1
Boardman 1
Boscoreale 1
Brooklyn 1
Buffalo 1
Capão da Canoa 1
Castrovillari 1
Chandīgarh 1
Clarksburg 1
Cleveland 1
Croydon 1
Cuauhtémoc 1
Decollatura 1
Des Moines 1
Dongyang 1
Falkenstein 1
Fiumicino 1
Florence 1
Forlì 1
Fuzhou 1
González Catán 1
Hamburg 1
Istanbul 1
Itabira 1
Jiaxing 1
Kansas City 1
Laguna 1
Mainz 1
Manchester 1
Marigliano 1
Mexico City 1
Montevideo 1
Montreal 1
Mosul 1
Noci 1
Norwalk 1
Nuremberg 1
Oakland 1
Pindamonhangaba 1
Redmond 1
San Francisco 1
San Giovanni la Punta 1
San Severo 1
Shanghai 1
Shenzhen 1
Sofia 1
Springfield 1
Sydney 1
Teresina 1
Três Rios 1
Villa San Giovanni 1
Vilnius 1
Vitória da Conquista 1
Votorantim 1
Warsaw 1
Wernigerode 1
Zapotlán el Grande 1
Zhuhai 1
Totale 355
Nome #
A Partial Phenotype of adFNDI Related to the Signal Peptide c.55G>A Variant of the AVP Gene 48
Mutational Analysis of the AVP Gene in a Calabrian Family Affected by adFNDI 45
diagnostics 44
Endocrines 41
Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes 41
Coexistence of Hashimoto’s Thyroiditis in Differentiated Thyroid Cancer: Post-Operative Monitoring of Anti-Thyroglobulin Antibodies and Assessment of Treatment Response 35
Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes 34
Gestational diabetes: Implications for fetal growth, intervention timing, and treatment options 33
Plasma or Urine Neutrophil Gelatinase-Associated Lipocalin (NGAL): Which Is Better at Detecting Chronic Kidney Damage in Type 2 Diabetes? 31
2-s2.0-85151325029 26
Endocrines 26
Metformin in Gestational Diabetes Mellitus: To Use or Not to Use, That Is the Question 26
Maternal Preconception Body Mass Index Overtakes Age as a Risk Factor for Gestational Diabetes Mellitus 21
Prothymosin-Alpha, a Novel and Sensitive Biomarker of the Inflammatory and Insulin-Resistant Statuses of Obese Individuals: A Pilot Study Involving Humans 20
Clinical Risk Factors and First Gestational 75g OGTT May Predict Recurrent and New-Onset Gestational Diabetes in Multiparous Women 19
Current Opinion in Pharmacology 18
Association Between Euthyroidism and Muscular Parameters in Adults with an Excess of Fat Mass: A Preliminary Study 17
The Initial ATA Risk Classification, but Not the AJCC/TNM Stage, Predicts the Persistence or Relapse of Differentiated Thyroid Cancer in Long-Term Surveillance 15
Clinical Risk Factors and First Gestational 75 g OGTT May Predict Recurrent and New-Onset Gestational Diabetes in Multiparous Women 10
Totale 550
Categoria #
all - tutte 5.240
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.240


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202130 0 0 0 0 0 0 0 1 8 5 6 10
2021/202220 5 2 0 2 0 2 0 2 5 0 1 1
2022/202360 10 9 1 4 2 3 0 1 20 3 7 0
2023/202469 9 4 7 2 6 15 11 0 1 1 8 5
2024/2025358 34 10 41 15 22 34 22 14 37 6 52 71
2025/202613 13 0 0 0 0 0 0 0 0 0 0 0
Totale 550